Edgestream Partners L.P. purchased a new stake in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 40,008 shares of the company’s stock, valued at approximately $1,145,000.
Other large investors have also added to or reduced their stakes in the company. TFC Financial Management Inc. purchased a new stake in Progyny during the first quarter valued at about $42,000. Financial Management Professionals Inc. purchased a new position in shares of Progyny in the first quarter worth about $52,000. Cambridge Trust Co. purchased a new position in shares of Progyny in the first quarter worth about $95,000. Natixis Investment Managers International purchased a new position in shares of Progyny in the first quarter worth about $117,000. Finally, 1620 Investment Advisors Inc. purchased a new position in shares of Progyny in the second quarter worth about $97,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.
Progyny Stock Performance
Progyny stock opened at $16.62 on Friday. The stock’s 50 day simple moving average is $24.33 and its two-hundred day simple moving average is $28.78. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of 27.25, a PEG ratio of 1.97 and a beta of 1.45. Progyny, Inc. has a fifty-two week low of $13.93 and a fifty-two week high of $42.08.
Insider Buying and Selling at Progyny
In other Progyny news, President Michael E. Sturmer sold 9,030 shares of Progyny stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $30.00, for a total transaction of $270,900.00. Following the sale, the president now directly owns 362,583 shares of the company’s stock, valued at approximately $10,877,490. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Cheryl Scott sold 1,462 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $28.39, for a total value of $41,506.18. Following the sale, the director now directly owns 10,098 shares of the company’s stock, valued at approximately $286,682.22. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, President Michael E. Sturmer sold 9,030 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $30.00, for a total value of $270,900.00. Following the completion of the sale, the president now directly owns 362,583 shares in the company, valued at $10,877,490. The disclosure for this sale can be found here. Insiders own 12.30% of the company’s stock.
Analyst Ratings Changes
Several research analysts have recently commented on PGNY shares. Cantor Fitzgerald decreased their price objective on Progyny from $37.00 to $25.00 and set an “overweight” rating on the stock in a report on Thursday. Truist Financial decreased their price objective on Progyny from $33.00 to $26.00 and set a “buy” rating on the stock in a report on Thursday. Canaccord Genuity Group decreased their price objective on Progyny from $24.00 to $18.00 and set a “hold” rating on the stock in a report on Friday. BTIG Research downgraded Progyny from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. Finally, Canaccord Genuity Group downgraded Progyny from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $37.00 to $24.00 in a report on Wednesday, August 7th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Progyny presently has a consensus rating of “Hold” and an average target price of $27.73.
Read Our Latest Analysis on Progyny
Progyny Company Profile
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Further Reading
- Five stocks we like better than Progyny
- Best Stocks Under $5.00
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.